Novartis gets U.S. nod for long-delayed copycat version of Amgen billion seller Neulasta drug Medical Dialogues Bureau6 Nov 2019 10:32 AM ISTZURICH: Novartis on Tuesday won U.S. approval for its long-delayed version of Amgen's $4 billion seller Neulasta drug, helping the Swiss drugmaker in...
Sumitomo Dainippon Pharma to acquire 10pc stake in Roivant Sciences for USD 3 billion Medical Dialogues Bureau7 Sept 2019 9:00 AM ISTThe deal, which will open up new drug lines for Sumitomo Dainippon, will also give it the option to acquire interests in an additional six businesses,...
Novartis sees gene, cell therapy reaching up to 15pc of total revenue in midterm Medical Dialogues Bureau5 Sept 2019 9:15 AM ISTZURICH: Novartis sees cell and gene therapies accounting for up to 15% of its total revenue in the midterm from a much lower level at present, a Swiss...
Roche names Eli Lilly executive Levi Garraway as chief medical officer Medical Dialogues Bureau20 Aug 2019 9:00 AM ISTLevi Garraway, most recently Eli Lilly's senior vice president, oncology research and development and Lilly research laboratories novel target...
Roche personalized cancer treatment Rozlytrek priced at Rs 12 lakh per month Medical Dialogues Bureau17 Aug 2019 9:15 AM ISTRozlytrek was approved by the U.S. Food and Drug Administration on Thursday to treat certain types of solid tumours, which show rare genetic anomalies...
Novartis concealed data problem before seeking approval for USD 2.1 million gene therapy Zolgensma: USFDA Medical Dialogues Bureau8 Aug 2019 9:15 AM ISTThe FDA said in a statement that AveXis Inc., the Novartis AG subsidiary that manufactures Zolgensma, told the agency five weeks after the approval of...
Novartis CEO sets aside 700 Million Dollar to settle doctor bribery lawsuit Medical Dialogues Bureau20 July 2019 9:52 AM ISTZURICH: Novartis Chief Executive Vas Narasimhan set aside $700 million to settle a U.S. doctor bribery lawsuit, as the Swiss drugmaker seeks to close...
Novartis Aimovig not cost effective: UK price watchdog Medical Dialogues Bureau11 Jan 2019 9:00 AM ISTNovartis, whose U.K. price for Aimovig is about 5,000 pounds ($6,374) annually but which was offering discounts, is counting on the medicine to be a...
